Literature DB >> 7293791

Single dose pharmacokinetics of doxepin in healthy volunteers.

R Virtanen, M Scheinin, E Iisalo.   

Abstract

The pharmacokinetics of orally administered doxepin (50 mg) was studied in 8 healthy volunteers. Doxepin (DOX) and desmethyldoxepin (DDOX) concentrations in serum (or plasma) and red blood cells (RBCs) were measured by radioimmunoassay. Peak serum concentrations of DOX were observed at 1-2 hours and they ranged between 59.1-107.4 nmol/1. DOX disappearance was biphasic with a mean distribution half-life of 2.0 hrs and elimination half-life of 17.9 hrs. The mean total apparent volume of distribution was 22.7 l/kg and plasma clearance 0.93 l/hr/kg. The estimated mean first-pass metabolism of DOX was 71% assuming complete absorption. Peak DDOX concentrations were observed at 1-6 hours and they ranged between 35.0-117.8 nmol/l. DDOX elimination was monophasic with a mean apparent half-life of 28.5 hours. Equilibrium dialysis gave a mean protein binding of 75.5% for DOX and 76.0% for DDOX. A highly time dependent and interindividually variable RBC/plasma concentration ratio was observed for both substances. Initially the plasma concentrations were 3-4 times higher than the respective RBC concentrations, but at later time points more DOX and DDOX could be found from the RBCs than from plasma. The major reason for this seemed to be a slower elimination of both drugs from the erythrocytes than from plasma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7293791     DOI: 10.1111/j.1600-0773.1980.tb01575.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  5 in total

1.  The influence of cimetidine versus ranitidine on doxepin pharmacokinetics.

Authors:  D L Sutherland; A J Remillard; K R Haight; M A Brown; L Old
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 2.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 3.  Low-dose doxepin: in the treatment of insomnia.

Authors:  Juliane Weber; M Asif A Siddiqui; Antona J Wagstaff; Paul L McCormack
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

4.  Stereoselective pharmacokinetics of doxepin isomers.

Authors:  K K Midha; J W Hubbard; G McKay; E M Hawes; E D Korchinski; T Gurnsey; J K Cooper; R Schwede
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  The pharmacologic management of insomnia in patients with HIV.

Authors:  Toma S Omonuwa; Harold W Goforth; Xavier Preud'homme; Andrew D Krystal
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.